Vor Biopharma: A Funded Replication Story With Franchise Potential

Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust $514.5M liquidity position. VOR's global Phase 3 trials in myasthenia gravis and Sjögren's are fully enrolled or underway, with topline MG data expected in H1 2027. Competitive pressures from argenx, Amgen, and Novartis require VOR to demonstrate differentiated efficacy, safety, and physician trust for commercial success.

Seeking Alpha • Sep 18, 2026

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha • Sep 9, 2026

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Topline results from UPSTREAM MG's 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacicept development across the myasthenia gravis (MG) spectrum; first patient dosing anticipated in the first half of 2027 BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the completion of enrollment in UPSTREAM MG, its global Phase 3 registrational trial evaluating telitacicept for the treatment of generalized myasthenia gravis (gMG).

GlobeNewsWire • Sep 8, 2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 17,900 shares of Vor Bio's common stock to 6 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

GlobeNewsWire • Sep 4, 2026

Vor Bio To Participate in Upcoming September Conferences

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference                         Forum: Fireside Chat and 1x1 Meetings                        Date: Tuesday, September 8th                        Presentation Time: 8:00AM ET Citi's 2026 Biopharma Back to School Conference                         Forum: Fireside Chat and 1x1 Meetings                        Date: Wednesday, September 9th                         Presentation Time: 11:20AM ET Morgan Stanley 24th Annual Global Healthcare Conference                         Forum: 1x1 Meetings                        Date: Monday, September 14th Baird's 2026 Global Healthcare Conference                         Forum: Presentation and 1x1 Meetings                        Date: Tuesday, September 15th                         Presentation Time: 9:05AM ET Stifel's 2026 Virtual Immunology and Inflammation Forum                         Forum: Presentation and 1x1 Meetings                        Date: Wednesday, September 23rd                        Presentation Time: 11:30AM ET A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com.

GlobeNewsWire • Sep 1, 2026

Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren's disease Pro-forma cash and investment balance of $514.5 million expected to provide runway into early 2029 BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “We continued to make meaningful progress in 2026 with telitacicept receiving its fourth and fifth commercial approvals in China for the treatment of Sjögren's disease and IgA nephropathy and its Phase 3 TELIGAN trial in IgA nephropathy being featured in The New England Journal of Medicine.

GlobeNewsWire • Aug 11, 2026

Vor Bio Appoints David Zaccardelli to Board of Directors

BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch.

GlobeNewsWire • Jul 7, 2026

Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes

Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitacicept, a dual BAFF/APRIL inhibitor with multiple China approvals. VOR holds $491.5 million in cash, providing runway through early 2029 and enabling Phase 3 clinical trial readouts in gMG and Sjögren's disease before requiring additional capital. Telitacicept's differentiation lies in upstream B-cell pathway inhibition, with promising efficacy signals across gMG, SjD, and IgAN, but faces intense competition and regulatory translation risk.

Seeking Alpha • Jul 7, 2026

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)  Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England Journal of Medicine IgAN marks the fourth indication approval for telitacicept BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331) today announced that China's National Medicinal Products Administration (NMPA) has conditionally approved telitacicept for the treatment of adult patients with IgAN.

GlobeNewsWire • Jun 8, 2026

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI SjD marks the fifth indication approval for telitacicept BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331) today announced that China's National Medicinal Products Administration (NMPA) has approved telitacicept for the treatment of adult patients with SjD.

GlobeNewsWire • Jun 8, 2026